NASDAQ:INGN Inogen Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Inogen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $28.77 +0.16 (+0.56 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$27.91Now: $28.77▼$29.1150-Day Range$27.01MA: $30.20▼$34.9052-Week Range$26.57Now: $28.77▼$76.89Volume507,685 shsAverage Volume369,511 shsMarket Capitalization$634.84 millionP/E Ratio95.90Dividend YieldN/ABeta0.78 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; and Inogen At Home stationary oxygen concentrators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California.Read More Beat the Market (BTM) Rank™ 2.9 Analyst's Opinion Consensus RatingInogen has received a consensus rating of Hold. The company's average rating score is 1.75, and is based on no buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $51.67, Inogen has a forecasted upside of 79.6% from its current price of $28.77.Amount of Analyst CoverageInogen has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesInogen has received 371 “outperform” votes. (Add your “outperform” vote.)Underperform VotesInogen has received 249 “underperform” votes. (Add your “underperform” vote.)Community SentimentInogen has received 59.84% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Inogen and other stocks. Vote “Outperform” if you believe INGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe INGN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldInogen does not currently pay a dividend.Dividend GrowthInogen does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inogen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.83% of the stock of Inogen is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Inogen are expected to grow in the coming year, from ($0.08) to $0.18 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inogen is 95.90, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 18.91.Price to Earnings Ratio vs. SectorThe P/E ratio of Inogen is 95.90, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.05.Price to Book Value per Share RatioInogen has a P/B Ratio of 1.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.9Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.30 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INGN Previous Symbol CUSIPN/A CIK1294133 Webwww.inogen.com Phone805-562-0500Debt Debt-to-Equity RatioN/A Current Ratio5.98 Quick Ratio5.27Price-To-Earnings Trailing P/E Ratio95.90 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$361.94 million Price / Sales1.75 Cash Flow$1.82 per share Price / Cash Flow15.81 Book Value$15.67 per share Price / Book1.84Profitability EPS (Most Recent Fiscal Year)$1.07 Net Income$20.95 million Net Margins1.96% Return on Equity2.68% Return on Assets2.05%Miscellaneous Employees1,020 Outstanding Shares22,066,000Market Cap$634.84 million Next Earnings Date11/3/2020 (Estimated) OptionableOptionable $28.77 +0.16 (+0.56 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive INGN News and Ratings via Email Sign-up to receive the latest news and ratings for INGN and its competitors with MarketBeat's FREE daily newsletter. Inogen (NASDAQ:INGN) Frequently Asked Questions How has Inogen's stock been impacted by COVID-19? Inogen's stock was trading at $40.61 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, INGN stock has decreased by 29.2% and is now trading at $28.77. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Inogen? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 1 sell rating and 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Inogen. When is Inogen's next earnings date? Inogen is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Inogen. How were Inogen's earnings last quarter? Inogen Inc (NASDAQ:INGN) released its quarterly earnings results on Tuesday, August, 4th. The medical technology company reported $0.12 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.08) by $0.20. The medical technology company had revenue of $71.70 million for the quarter, compared to the consensus estimate of $79.96 million. Inogen had a net margin of 1.96% and a return on equity of 2.68%. The company's revenue for the quarter was down 29.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.45 EPS. View Inogen's earnings history. What price target have analysts set for INGN? 4 analysts have issued 12 month price objectives for Inogen's shares. Their forecasts range from $35.00 to $75.00. On average, they anticipate Inogen's stock price to reach $51.67 in the next twelve months. This suggests a possible upside of 79.6% from the stock's current price. View analysts' price targets for Inogen. Who are some of Inogen's key competitors? Some companies that are related to Inogen include Avanos Medical (AVNS), Establishment Labs (ESTA), Invacare (IVC), RTI Surgical (RTIX), Alpha Pro Tech (APT), Sientra (SIEN), Lakeland Industries (LAKE), ConforMIS (CFMS), COLLPLANT HOLDI/S (CLGN), Histogenics (HSGX), Rewalk Robotics (RWLK), Allied Healthcare Products (AHPI), Advanced Biomedical Technologies (ABMT), Precision Therapeutics (POAI) and Bionik Laboratories (BNKL). View all competitors. What other stocks do shareholders of Inogen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), Incyte (INCY), Medivation (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Intel (INTC), Netflix (NFLX) and First Solar (FSLR). Who are Inogen's key executives? Inogen's management team includes the following people: Mr. Scott Wilkinson, CEO, Pres & Director (Age 54)Mr. Brenton Taylor, Co-founder & Exec. VP of Engineering (Age 38)Ms. Alison Perry Bauerlein, Co-founder, Exec. VP of Fin., CFO, Corp. Sec. & Treasurer (Age 38)Mr. Bart Sanford, Exec. VP of Operations (Age 53)Mr. Byron Myers, Exec. VP of Sales & Marketing (Age 40) What is Inogen's stock symbol? Inogen trades on the NASDAQ under the ticker symbol "INGN." Who are Inogen's major shareholders? Inogen's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.98%), Goldman Sachs Group Inc. (1.67%), Bamco Inc. NY (1.63%), Two Sigma Advisers LP (1.26%), Rockefeller Capital Management L.P. (1.24%) and Riverbridge Partners LLC (1.19%). Company insiders that own Inogen stock include Brenton Taylor, Heath Lukatch, Loren L Mcfarland, Ray Benjamin M Anderson and Raymond Huggenberger. View institutional ownership trends for Inogen. Which institutional investors are selling Inogen stock? INGN stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Balyasny Asset Management LLC, Beacon Investment Advisory Services Inc., Vanguard Group Inc., Russell Investments Group Ltd., Two Sigma Advisers LP, Bank of America Corp DE, and Rockefeller Capital Management L.P.. View insider buying and selling activity for Inogen. Which institutional investors are buying Inogen stock? INGN stock was acquired by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Assenagon Asset Management S.A., Bamco Inc. NY, Grantham Mayo Van Otterloo & Co. LLC, Engineers Gate Manager LP, Bellevue Group AG, Hussman Strategic Advisors Inc., and Goldman Sachs Group Inc.. Company insiders that have bought Inogen stock in the last two years include Heath Lukatch, and Loren L Mcfarland. View insider buying and selling activity for Inogen. How do I buy shares of Inogen? Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Inogen's stock price today? One share of INGN stock can currently be purchased for approximately $28.77. How big of a company is Inogen? Inogen has a market capitalization of $634.84 million and generates $361.94 million in revenue each year. The medical technology company earns $20.95 million in net income (profit) each year or $1.07 on an earnings per share basis. Inogen employs 1,020 workers across the globe. What is Inogen's official website? The official website for Inogen is www.inogen.com. How can I contact Inogen? Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at 805-562-0500 or via email at [email protected] This page was last updated on 9/19/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
